{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:07:02Z","timestamp":1790701622964,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jpet.2026.104992","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:49:54Z","timestamp":1784908194000},"page":"104992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["RRx-001 sensitizes triple-negative breast cancer cells to oxaliplatin through apoptosis, cell cycle arrest, and immune modulation"],"prefix":"10.1016","volume":"393","author":[{"given":"Rafid K.","family":"Al-Fatlawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4451-8939","authenticated-orcid":false,"given":"Wrood S.","family":"AL-khfajy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jpet.2026.104992_bib1","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.jpet.2026.104992_bib2","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clinicians"},{"issue":"7","key":"10.1016\/j.jpet.2026.104992_bib3","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple negative breast cancer treatment options and limitations: future outlook","volume":"15","author":"Obidiro","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpet.2026.104992_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.semcancer.2019.09.012","article-title":"Drug repurposing for breast cancer therapy: old weapon for new battle","volume":"68","author":"Aggarwal","year":"2021","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104992_bib5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jpet.2026.104992_bib6","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","article-title":"The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs","volume":"116","author":"Johnstone","year":"2016","journal-title":"Chem Rev"},{"issue":"2","key":"10.1016\/j.jpet.2026.104992_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","article-title":"Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis","volume":"5","author":"Feng","year":"2018","journal-title":"Genes Dis"},{"issue":"4","key":"10.1016\/j.jpet.2026.104992_bib8","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.3390\/ijms22042056","article-title":"Effect of oxaliplatin, olaparib and LY294002 in combination on triple-negative breast cancer cells","volume":"22","author":"Andreidesz","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.jpet.2026.104992_bib9","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s13402-020-00552-2","article-title":"Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy","volume":"43","author":"Zhu","year":"2020","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"10.1016\/j.jpet.2026.104992_bib10","article-title":"Oxaliplatin induces immunogenic cell death in human and murine laryngeal cancer","volume":"2022","author":"Wang","year":"2022","journal-title":"J Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.jpet.2026.104992_bib11","article-title":"1252 platin-based chemotherapies effectively induce an immunogenic cell death in preclinical models of triple negative breast cancer","volume":"13","author":"Hassan","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"30","key":"10.1016\/j.jpet.2026.104992_bib12","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2217\/fon-2019-0317","article-title":"REPLATINUM phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer","volume":"15","author":"Oronsky","year":"2019","journal-title":"Future Oncol"},{"issue":"11","key":"10.1016\/j.jpet.2026.104992_bib13","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1021\/acs.jmedchem.1c00599","article-title":"Discovery of RRx-001, a Myc and CD47 downregulating small molecule with tumor targeted cytotoxicity and healthy tissue cytoprotective properties in clinical development","volume":"64","author":"Oronsky","year":"2021","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.jpet.2026.104992_bib14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(15)00089-3","article-title":"Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study","volume":"16","author":"Reid","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104992_bib15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/compounds3030035","article-title":"Thermodynamic overview of bioconjugation reactions pertinent to lysine and cysteine peptide and protein residues","volume":"3","author":"Lopandic","year":"2023","journal-title":"Compounds"},{"issue":"11","key":"10.1016\/j.jpet.2026.104992_bib16","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.7150\/ijms.76615","article-title":"Superficial venous-associated inflammation from direct IV administration of RRx-001 in rats","volume":"19","author":"Caroen","year":"2022","journal-title":"Int J Med Sci"},{"issue":"5","key":"10.1016\/j.jpet.2026.104992_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-023-01838-z","article-title":"A review of RRx-001: a late-stage multi-indication inhibitor of NLRP3 activation and chronic inflammation","volume":"83","author":"Jayabalan","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.jpet.2026.104992_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1204143","article-title":"RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist","volume":"13","author":"Oronsky","year":"2023","journal-title":"Front Oncol"},{"issue":"41","key":"10.1016\/j.jpet.2026.104992_bib19","doi-asserted-by":"crossref","first-page":"43172","DOI":"10.18632\/oncotarget.6526","article-title":"Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity","volume":"6","author":"Zhao","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.jpet.2026.104992_bib20","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.tranon.2018.12.001","article-title":"RRx-001 acts as a dual small molecule checkpoint inhibitor by downregulating CD47 on cancer cells and SIRP-\u03b1 on monocytes\/macrophages","volume":"12","author":"Cabrales","year":"2019","journal-title":"Transl Oncol"},{"issue":"6","key":"10.1016\/j.jpet.2026.104992_bib21","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41423-021-00683-y","article-title":"RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor","volume":"18","author":"Chen","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jpet.2026.104992_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13148-017-0312-z","article-title":"The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry","volume":"9","author":"Zhao","year":"2017","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.jpet.2026.104992_bib23","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.3389\/fphar.2019.01485","article-title":"Systemic evaluation on the pharmacokinetics of platinum-based anticancer drugs from animal to cell level: based on total platinum and intact drugs","volume":"10","author":"Qin","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpet.2026.104992_bib24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.31351\/vol32issSuppl.pp136-144","article-title":"Synergistic effects of 2-deoxy-D-glucose and cinnamic acid with erlotinib on NSCLC cell line","volume":"32","author":"Salim Al-khfajy","year":"2023","journal-title":"Iraqi J Pharm Sci"},{"issue":"8","key":"10.1016\/j.jpet.2026.104992_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103654","article-title":"Cinnamic acid enhances vinorelbine-induced cytotoxicity in MDA-MB-231 cells through modulation of PTEN and ATG5 expression","volume":"392","author":"Al Mulla Hummadi","year":"2025","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.jpet.2026.104992_bib26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.31351\/vol32iss1pp115-124","article-title":"Role of fasting mimicking diet in Farnesoid x receptor for suppressing epithelial-to-mesenchymal transition, cell cycle progression, and viability of prostate cancer cells","volume":"32","author":"Wrood","year":"2023","journal-title":"Iraqi J Pharm Sci"},{"issue":"49","key":"10.1016\/j.jpet.2026.104992_bib27","first-page":"2573","article-title":"Clonogenic assay: adherent cells","volume":"13","author":"Rafehi","year":"2011","journal-title":"J Vis Exp"},{"issue":"7","key":"10.1016\/j.jpet.2026.104992_bib28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"issue":"5","key":"10.1016\/j.jpet.2026.104992_bib29","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4161\/cam.36224","article-title":"An introduction to the wound healing assay using live-cell microscopy","volume":"8","author":"Jonkman","year":"2014","journal-title":"Cell Adh Migr"},{"issue":"1","key":"10.1016\/j.jpet.2026.104992_bib30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/j.jpet.2026.104992_bib31","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"6535","key":"10.1016\/j.jpet.2026.104992_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/376037a0","article-title":"Identification and inhibition of the ICE\/CED-3 protease necessary for mammalian apoptosis","volume":"376","author":"Nicholson","year":"1995","journal-title":"Nature"},{"issue":"6495","key":"10.1016\/j.jpet.2026.104992_bib33","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/371346a0","article-title":"Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE","volume":"371","author":"Lazebnik","year":"1994","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.jpet.2026.104992_bib34","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: a review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans"},{"issue":"6","key":"10.1016\/j.jpet.2026.104992_bib35","article-title":"Recent advances in the molecular basis of chemotherapy resistance and potential application of epigenetic therapeutics in chemorefractory renal cell carcinoma","volume":"14","author":"Acharya","year":"2022","journal-title":"WIREs Mech Dis"},{"issue":"18","key":"10.1016\/j.jpet.2026.104992_bib36","doi-asserted-by":"crossref","first-page":"7617","DOI":"10.1021\/acs.jmedchem.6b01672","article-title":"Nitric oxide donor-based cancer therapy: advances and prospects","volume":"60","author":"Huang","year":"2017","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.jpet.2026.104992_bib37","article-title":"Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis","volume":"2019","author":"Su","year":"2019","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"10.1016\/j.jpet.2026.104992_bib38","doi-asserted-by":"crossref","first-page":"474","DOI":"10.37349\/edd.2024.00062","article-title":"Mitochondrial ROS, a trigger for mitochondrial dysfunction and inflammasome activation and a therapeutic target in liver diseases","volume":"3","author":"Jaara","year":"2024","journal-title":"Explor Dig Dis"},{"issue":"3","key":"10.1016\/j.jpet.2026.104992_bib39","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.jpet.2026.104992_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51537-7","article-title":"Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination","volume":"9","author":"Gilad","year":"2019","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.jpet.2026.104992_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf178","article-title":"DNA damage response regulator ATR licenses PINK1-mediated mitophagy","volume":"53","author":"Marx","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/j.jpet.2026.104992_bib42","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ceb.2005.08.002","article-title":"Cell migration in tumors","volume":"17","author":"Yamaguchi","year":"2005","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104992_bib43","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1038\/s41598-023-29363-9","article-title":"Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model","volume":"13","author":"Alimohammadi","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jpet.2026.104992_bib44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5114\/amscd.2018.81070","article-title":"The role of matrix metalloproteinases in cancer progression, in particular metastasis","volume":"3","author":"Alsayad","year":"2018","journal-title":"Arch Med Sci Civil Dis"},{"issue":"1","key":"10.1016\/j.jpet.2026.104992_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/srep31694","article-title":"A simple non-perturbing cell migration assay insensitive to proliferation effects","volume":"6","author":"Glenn","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.jpet.2026.104992_bib46","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/cimb47030172","article-title":"Multi-pathway study for oxaliplatin resistance reduction","volume":"47","author":"Ye","year":"2025","journal-title":"Curr Issues Mol Biol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:44:23Z","timestamp":1790700263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526011924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0022356526011924"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104992","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RRx-001 sensitizes triple-negative breast cancer cells to oxaliplatin through apoptosis, cell cycle arrest, and immune modulation","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104992"}}